Bristol-Myers Squibb Company (BMY)

45.32
0.08 0.18
NYSE
Prev Close 45.24
Open 45.34
Day Low/High 44.95 / 45.54
52 Wk Low/High 44.30 / 68.22
Volume 14.19M
Exchange NYSE
Shares Outstanding 1633.96B
Market Cap 74.38B
Div & Yield N.A. (N.A)

Latest News

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.

Bristol-Myers Squibb Shareholders Approve Celgene Acquisition

Bristol-Myers Squibb Shareholders Approve Celgene Acquisition

Bristol-Myers Squibb Company (NYSE: BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company's pending merger with Celgene Corporation (NASDAQ:CELG) at the...

Bristol-Myers Squibb Announces Long-Term Survival Results From Pooled Analyses Of Opdivo (nivolumab) In Previously-Treated Non-Small Cell Lung Cancer Patients

Bristol-Myers Squibb Announces Long-Term Survival Results From Pooled Analyses Of Opdivo (nivolumab) In Previously-Treated Non-Small Cell Lung Cancer Patients

Bristol-Myers Squibb Company (NYSE: BMY) today announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were...

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition

Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition

Celgene surges Friday after an influential shareholder advisory group recommend investors vote in favor of the cancer drug specialist's takeover by Bristol-Myers Squibb Co. while a key activist dropped its opposition to the $74 billion deal.

Bristol-Myers Squibb Issues Statement On Celgene's Settlement With Alvogen On Revlimid® Patent Litigation

Bristol-Myers Squibb Issues Statement On Celgene's Settlement With Alvogen On Revlimid® Patent Litigation

Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene's (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co.

Starboard Issues Statement On Bristol-Myers

Starboard Issues Statement On Bristol-Myers

NEW YORK, March 29, 2019 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), a shareholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY), today provided the following statement on its investment...

Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote "FOR" Proposed Merger With Celgene

Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote "FOR" Proposed Merger With Celgene

Bristol-Myers Squibb Company (NYSE:BMY) today announced that independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis & Co.

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Lots of IPOs and innovation will reward investors who do their homework, Jim Cramer says.

Starboard Mails Letter To All Bristol-Myers Squibb Shareholders

Starboard Mails Letter To All Bristol-Myers Squibb Shareholders

Starboard Asks Shareholders to NOT Allow Bristol-Myers to Bet the Company on a Highly-Risky and Likely Value-Destructive Acquisition

Bristol-Myers Squibb Becomes #231 Most Shorted S&P 500 Component, Replacing Wynn Resorts

Bristol-Myers Squibb Becomes #231 Most Shorted S&P 500 Component, Replacing Wynn Resorts

The most recent short interest data has been released for the 03/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal

Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal

Bristol-Myers Squibb says Tuesday the Federal Trade Commission has requested information related to its planned $74 billion takeover of cancer drug company Celgene.

Bristol-Myers Squibb, Xilinx, Nieslen: 'Mad Money' Lightning Round

Bristol-Myers Squibb, Xilinx, Nieslen: 'Mad Money' Lightning Round

Jim Cramer takes a look at Bristol-Myers Squibb, Xilinx, Nieslen, Realty Income, W&T Offshore and more.

What More Do They Want?: Cramer's 'Mad Money' Recap (Monday 3/25/19)

What More Do They Want?: Cramer's 'Mad Money' Recap (Monday 3/25/19)

Apple couldn't do much to hold back the bears today, but Jim Cramer says the company's services segment is the most important thing and he's more than happy with it.

Bristol-Myers Squibb Board Of Directors Sends Letter To Shareholders Highlighting The Compelling Strategic And Financial Rationale Of The Celgene Transaction; Company Provides Additional Investor Materials

Bristol-Myers Squibb Board Of Directors Sends Letter To Shareholders Highlighting The Compelling Strategic And Financial Rationale Of The Celgene Transaction; Company Provides Additional Investor Materials

Bristol-Myers Squibb Company's (NYSE:BMY) Board of Directors today sent an open letter to the Company's shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (NASDAQ:CELG).

Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

Bristol-Myers Squibb trades blows with activist investor Starboard Value Tuesday as the pair issues competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene.

Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer

Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer

Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.

Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

Here's what you need to know about Tilray's earnings, Elon Musk's fight with the SEC and Bristol-Myers fight with Starboard over Celgene. Jim Cramer talks the markets

Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition Of Celgene

Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition Of Celgene

Mails Definitive Proxy Materials and a BLUE Proxy Card for Shareholders to Vote AGAINST the Proposed Transaction at the Upcoming Special Meeting

Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits Of Pending Transaction With Celgene

Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits Of Pending Transaction With Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celgene Corporation (NASDAQ: CELG).

AUGUSTUS Demonstrates Favorable Safety Results Of Eliquis® Versus Vitamin K Antagonists In Non-Valvular Atrial Fibrillation Patients With Acute Coronary Syndrome And/or Undergoing Percutaneous Coronary Intervention

AUGUSTUS Demonstrates Favorable Safety Results Of Eliquis® Versus Vitamin K Antagonists In Non-Valvular Atrial Fibrillation Patients With Acute Coronary Syndrome And/or Undergoing Percutaneous Coronary Intervention

The Bristol-Myers Squibb- Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) and recent acute coronary...

Nvidia's Head-Turning Deal for Mellanox Technologies: 7 Takeaways

Nvidia's Head-Turning Deal for Mellanox Technologies: 7 Takeaways

Nvidia and Mellanox have many common customers, and also a major common competitor in Intel.

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty one cents ($0.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

TheStreet Quant Rating: C+ (Hold)